(-0.03%) 5 467.77 points
(-0.03%) 39 099 points
(0.26%) 17 763 points
(-0.54%) $80.39
(-4.32%) $2.64
(-0.85%) $2 311.00
(-0.05%) $28.86
(2.27%) $1 008.80
(0.27%) $0.936
(0.67%) $10.67
(0.47%) $0.792
(-0.28%) $87.25
Live Chart Being Loaded With Signals
Lexeo Therapeutics, Inc. operates as a clinical-stage genetic medicine company that focuses on hereditary and acquired diseases. The company develops LX2006, which is an AAVrh10-based gene therapy candidate for the treatment of Friedreich\'s ataxia (FA) cardiomyopathy; LX2020, an AAVrh10-based gene therapy candidate for the treatment of arrhythmogenic cardiomyopathy; LX2021, a gene therapy candidate for the treatment of DSP cardiomyopathy associated with it; and LX2022, a gene therapy candidate for the treatment of HCM caused by TNNI3 mutations...
Stats | |
---|---|
Today's Volume | 28 139 |
Average Volume | 145 361 |
Market Cap | 532.40M |
EPS | $-0.770 ( Q1 | 2024-03-31 ) |
Last Dividend | $0 ( N/A ) |
Next Dividend | $0 ( N/A ) |
P/E |
0 (Sector) 42.63 (Industry) 24.32 |
ATR14 | $0.0850 (0.52%) |
Date | Person | Action | Amount | type |
---|---|---|---|---|
2023-11-07 | Omega Fund Vi, L.p. | Buy | 454 545 | Common Stock |
2023-11-07 | Omega Fund Vi, L.p. | Buy | 287 213 | Common Stock |
2023-11-07 | Omega Fund Vi, L.p. | Buy | 1 415 865 | Common Stock |
2023-11-07 | Omega Fund Vi, L.p. | Sell | 2 615 533 | Series B convertible preferred stock |
2023-11-07 | Omega Fund Vi, L.p. | Sell | 14 999 999 | Series A convertible preferred stock |
INSIDER POWER |
---|
-79.48 |
Last 16 transactions |
Buy: 4 724 723 | Sell: 41 348 236 |
Volume Correlation
Lexeo Therapeutics, Inc. Correlation
10 Most Positive Correlations |
---|
10 Most Negative Correlations |
---|
Did You Know?
Correlation is a statistical measure that describes the relationship between two variables. It ranges from -1 to 1, where -1 indicates a perfect negative correlation (as one variable increases, the other decreases), 1 indicates a perfect positive correlation (as one variable increases, the other increases), and 0 indicates no correlation (there is no relationship between the variables).
Correlation can be used to analyze the relationship between any two variables, not just stocks. It's commonly used in fields such as finance, economics, psychology, and more.
Lexeo Therapeutics, Inc. Correlation - Currency/Commodity
Lexeo Therapeutics, Inc. Financials
Annual | 2022 |
Revenue: | $654 000 |
Gross Profit: | $654 000 (100.00 %) |
EPS: | $-2.40 |
FY | 2022 |
Revenue: | $654 000 |
Gross Profit: | $654 000 (100.00 %) |
EPS: | $-2.40 |
Financial Reports:
No articles found.
Contract Name | Last Trade Date (EDT) | Strike | Last Price | Bid | Ask | Change | % Change | Volume | Open Interest | Implied Volatility | Strike Date |
---|---|---|---|---|---|---|---|---|---|---|---|
No data available |
Contract Name | Last Trade Date (EDT) | Strike | Last Price | Bid | Ask | Change | % Change | Volume | Open Interest | Implied Volatility | Strike Date |
---|---|---|---|---|---|---|---|---|---|---|---|
No data available |
Lexeo Therapeutics, Inc.
Lexeo Therapeutics, Inc. operates as a clinical-stage genetic medicine company that focuses on hereditary and acquired diseases. The company develops LX2006, which is an AAVrh10-based gene therapy candidate for the treatment of Friedreich\'s ataxia (FA) cardiomyopathy; LX2020, an AAVrh10-based gene therapy candidate for the treatment of arrhythmogenic cardiomyopathy; LX2021, a gene therapy candidate for the treatment of DSP cardiomyopathy associated with it; and LX2022, a gene therapy candidate for the treatment of HCM caused by TNNI3 mutations. It also develops LX1001, an AAVrh10-based gene therapy candidate for the treatment of APOE4 homozygous; LX1020, a gene therapy candidate for the treatment of APOE4 homozygous; LX1021 for the treatment of APOE4 homozygotes; and LX1004 for the treatment of CLN2 Batten disease. The company was incorporated in 2017 and is based in New York, New York.
About Live Signals
The live signals presented on this page help determine when to BUY or SELL NA. The signals have upwards of a 1-minute delay; like all market signals, there is a chance for error or mistakes.
The live trading signals are not definite, and getagraph.com hold no responsibility for any action taken upon these signals, as described in the Terms of Use. The signals are based on a wide range of technical analysis indicators